CYP3A137P

Across TCGA pan-cancer cohorts, CYP3A137P RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated CYP3A137P data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher CYP3A137P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CYP3A137P expression acts as an unfavorable survival marker, although some lineages such as KIRC and LAML show a favorable association.

PAAD, DLBC, and ESCA are the cancer types where CYP3A137P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Tertile	All	0.132	0.613	.002	45	view →
DLBC	OS	Tertile	II,III,IV	0.175	0.843	.016	36	view →
ESCA	OS	Tertile	IV	0.095	0.512	.008	36	view →
GBM	DFS	Tertile	All	0.065	0.258	.003	18	view →
SARC	DFS	Tertile	All	0.148	0.613	.007	18	view →
KIRC	DFS	Tertile	III,IV	1.000	0.731	.034	12	view →
LAML	DFS	Tertile	All	1.000	0.533	.023	12	view →
LUAD	OS	Tertile	All	0.224	0.697	.035	9	view →
KICH	OS	Tertile	All	0.844	0.965	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CYP3A137P–PAAD (OS)

Open the PAAD breakdown →